Skip to content

Taysha Gene Therapies

US · TSHA #3015 by market cap Listed 2020
3.72 -0.05 -1.33%
Periodic snapshot; not a real-time feed. · 2026-11-20 20:02

About Taysha Gene Therapies

Taysha Gene Therapies, Inc. is a clinical-stage biotechnology company, which engages in the development and commercialization of adeno-associated viruses (AAV) based gene therapies for the treatment of monogenic diseases of the central nervous system. It also develops multiple gene therapy platforms which include AAV9 Discovery, Novel Capsid, and AAV Redosing. The company was founded by Steven Gray, Berge Minassian, and R. A. Session II in 2019 and is headquartered in Dallas, TX.

Founded
2019
CEO
Mr. Sean P. Nolan
Employees
99
Headquarters
Dallas, Texas, United States of America
Fiscal year end
12-31
Website
tayshagtx.com

Company profile

Exchange
US
Symbol
TSHA
Market-cap rank
#3015
Listing date
2020-09-24
Market cap
1.21B
Float cap
845.64M
Shares out
326.05M
Float shares
227.32M

Sectors & themes

Browse all sectors & themes

Quote time 2026-11-20 20:02:39 · For reference only, not investment advice and not tailored to your situation.

Taysha Gene Therapies discussion 0 comments

Add a comment